Journey Medical (DERM)
(Delayed Data from NSDQ)
$6.17 USD
+0.42 (7.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $6.16 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Income Statements
Fiscal Year end for Journey Medical Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 79 | 74 | 63 | 45 | 35 |
Cost Of Goods | 27 | 31 | 32 | 15 | 11 |
Gross Profit | 53 | 43 | 31 | 30 | 24 |
Selling & Adminstrative & Depr. & Amort Expenses | 55 | 70 | 66 | 22 | 19 |
Income After Depreciation & Amortization | -2 | -28 | -35 | 8 | 5 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 2 | 2 | 7 | 1 | 0 |
Pretax Income | -4 | -30 | -42 | 7 | 5 |
Income Taxes | 0 | 0 | 2 | 2 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -4 | -30 | -44 | 5 | 4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -4 | -30 | -44 | 5 | 4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 5 | -23 | -30 | 9 | 7 |
Depreciation & Amortization (Cash Flow) | 7 | 4 | 5 | 2 | 1 |
Income After Depreciation & Amortization | -2 | -28 | -35 | 8 | 5 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 18.23 | 17.53 | 10.19 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.21 | -1.69 | -4.32 | NA | NA |
Diluted Net EPS (GAAP) | -0.21 | -1.69 | -4.32 | 0.49 | NA |
Fiscal Year end for Journey Medical Corporation falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 14.86 | 13.03 | 15.26 | 34.54 |
Cost Of Goods | NA | 6.54 | 6.82 | 6.01 | 6.43 |
Gross Profit | NA | 8.31 | 6.21 | 9.24 | 28.11 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 11.24 | 16.30 | 11.35 | 10.87 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.93 | -10.09 | -2.11 | 17.24 |
Non-Operating Income | NA | 0.13 | 0.20 | 0.11 | -0.09 |
Interest Expense | NA | 0.56 | 0.55 | 0.02 | 0.27 |
Pretax Income | NA | -3.36 | -10.44 | -2.02 | 16.88 |
Income Taxes | NA | 0.00 | 0.00 | 0.13 | 0.10 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.36 | -10.44 | -2.14 | 16.79 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.36 | -10.44 | -2.14 | 16.79 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 19.99 | 19.76 | 18.23 | 21.04 |
Diluted EPS Before Non-Recurring Items | NA | -0.17 | -0.53 | -0.12 | 0.80 |
Diluted Net EPS (GAAP) | NA | -0.17 | -0.53 | 0.02 | 0.80 |